Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.
Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.
Biopharmas raising money in public or private financings, including: Differentiated, Fennec, Glubio, Nuvectis, Obseva, Oricell, Revelation, Structure, Synthetic and Trevena.
The $65 million series A money banked by Vicinitas Therapeutics Inc. will boost efforts with the company’s Deubiquitinase Targeting Chimera (DUBTAC) platform, developed by way of an academic-industry research collaboration between the Novartis Institutes for Biomedical Research and researchers at the University of California, Berkeley.
RSS
